LONDON (Alliance News) - Drug discovery and development company Redx Pharma PLC Thursday welcomed the publication of a paper on antimicrobial resistance, chaired by Jim O'Neill.
The paper sets out recommendations to tackle the problem of antimicrobial resistance, and sets out a ten point plan to tackle the issue.
Redx said it "fully supports" the plan, especially recommendations aimed at increasing the number of effective antimicrobial drugs. It said that this is a task it has been "working hard to achieve", and it therefore welcomes the proposal to establish a global innovation fund for such research and better incentives to promote investment for new drugs and the improvement of existing drugs.
"The review marks an important step forward, and we see significant potential for the Innovation Fund and new commercialisation models. It is now the collective responsibility of all members of society to ensure these changes are implemented to avoid the consequences of antibiotics failing," said Chief Executive Neil Murray in a statement.
Shares in Redx were down 0.2% at 30.45 pence Thursday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
